ArticlePloS one2025
Zinc finger protein 800 (ZNF800) promotes proliferation and migration of lower-grade glioma and is associated with immune infiltration.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
ZNF800 is a novel gene affecting the malignant progression of several cancers. However, the involvement of ZNF800 in the malignant evolution of lower-grade gliomas (LGG) and poor prognosis of patients remains unclear. This study comprehensively revealed the association between ZNF800 and LGG malignant progression by analyzing 958 clinical samples from multiple public databases. The mRNA and protein expression levels of ZNF800 were higher in LGG tissues than in non-LGG tissues and were associated with malignant clinical features associated with a poor prognosis. High ZNF800 expression was closely related to the infiltration of some immune cells, particularly CD8 + T cells and dendritic cell activation. ZNF800 was positively associated with several immune checkpoint genes, such as CD274 and PDCD1 encoding PD-1 and PD-L1, respectively. Moreover, knocking down ZNF800 can significantly inhibit the proliferation and invasion ability of glioma cells. Therefore, ZNF800 can be used as an effective biomarker for LGG diagnosis and prognosis and can provide a theoretical basis for potential targets of combined immunotherapy in patients with LGG.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.